Cannabidiol (CBD), the primary non-psychoactive constituent of cannabis plants, has emerged as a research focus in neuropsychiatric disorders in recent years due to its multi-target regulatory properties. This review summarizes the potential therapeutic targets of CBD and its current application in common neuropsychiatric disorders so as to promote clinical implementation of CBD in managing neuropsychiatric disorders.

Cannabidiol (CBD), the primary non-psychoactive constituent of cannabis plants, has emerged as a research focus in neuropsychiatric disorders in recent years due to its multi-target regulatory properties. This review summarizes the potential therapeutic targets of CBD and its current application in common neuropsychiatric disorders so as to promote clinical implementation of CBD in managing neuropsychiatric disorders.